Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Arcturus Therapeutics (ARCT) reported a Q3 loss of $0.26 per share, which was better than the Zacks Consensus Estimate of a $0.70 loss. However, the company lagged in revenue estimates.
November 08, 2024 | 12:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcturus Therapeutics reported a Q3 loss of $0.26 per share, better than expected, but missed revenue estimates.
The better-than-expected EPS loss is a positive sign, but missing revenue estimates could offset this. The stock may see mixed reactions as investors weigh these factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100